Quest Diagnostics is a leading global provider of diagnostic information services, specializing in laboratory testing and related services. The company offers a comprehensive range of medical testing, including routine blood work, genetic testing, and specialized diagnostic imaging, aimed at helping healthcare providers make informed decisions about patient care. With a vast network of laboratories and patient service centers, Quest Diagnostics plays a critical role in the healthcare ecosystem by delivering accurate and timely results, contributing to enhanced patient outcomes and supporting public health initiatives. Through their innovative technologies and dedication to quality, the company strives to advance the practice of medicine and improve overall health management. Read More
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session.
Curious about the market action on Tuesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
The laboratory operator reported first-quarter adjusted diluted EPS of $2.21, representing an 8.3% growth from the corresponding period last year and meeting an analyst estimate of $2.21, according to Finchat data.
Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 12.1% year on year to $2.65 billion. The company expects the full year’s revenue to be around $10.78 billion, close to analysts’ estimates. Its non-GAAP profit of $2.21 per share was 2.8% above analysts’ consensus estimates.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 15.5%. This drop was worse than the S&P 500’s 10% fall.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting with Guardant Health (NASDAQ:GH).
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the testing & diagnostics services stocks, including NeoGenomics (NASDAQ:NEO) and its peers.
While the S&P 500 includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
